Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Gilead Japan Building Sales Force to Prep for Full Oncology Entry: Chief
July 14, 2023
- Enhertu Adds HER2 Low Breast Cancer Nod in China
July 14, 2023
- Daiichi Sankyo Espha Rolls Out Follow-On AG for Maintate
July 13, 2023
- Organon to Succeed Bepricor Distribution from Daiichi Sankyo in Japan
July 13, 2023
- Astellas’ Iveric Bio Acquisition Completed
July 13, 2023
- Generic Makers, Industry, and Govt Must Join Hands to Build Long-Term Stable Supply System: Towa Chief
July 13, 2023
- Meiji to Develop Lineup Unaffected by Price Revisions, Bolster Earnings from New Drugs/Generics in Focus Areas
July 12, 2023
- SanBio to Ax 22 Jobs in US, Focus on Work towards Japan Cell Therapy Launch
July 12, 2023
- RaQualia’s Acid Reducer Tegoprazan Launched in Indonesia
July 12, 2023
- JCR Grabs German OK for Launch of Global PI/II for MPS IIIA Drug
July 12, 2023
- Eisai’s Alzheimer’s Skipper to Retire after Full Leqembi Approval
July 12, 2023
- Astellas Bags Rights to 4DMT’s Gene Therapy Vector for Eye Diseases
July 12, 2023
- Shionogi to Cut 200 Jobs via Voluntary Buyout Program
July 11, 2023
- Japan Ethical Drug Sales Up 7.2% in May: Crecon
July 10, 2023
- Full US Nod in Hand, Eisai CEO Keeps 1 Trillion Yen Sales Target for FY2030
July 10, 2023
- Pfizer, Moderna File Updated COVID-19 Vaccines in Japan
July 7, 2023
- Meiji/Zeria Grabs Thai Approval for Functional Dyspepsia Drug
July 7, 2023
- Astellas’ 1st-in-Class Gastric Cancer Med Bags Priority Review in US
July 7, 2023
- Opdivo Extends Streak of Best-Seller Title to 18 Months: Encise
July 7, 2023
- FDA Awards Full Approval to Eisai’s Alzheimer’s Drug
July 7, 2023
ページ
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…